The DCE-MRI δKtrans Biomarker Provides Early Prediction of Soft-Tissue Sarcoma Response to Anti-Angiogenic Therapy

Janelle M. Meyer¹, Brooke R. Beckett¹, Xin Li¹, Luminita A. Tudorica¹, Aneela Afzal¹, Stephanie Hemmingson¹, Yiyi Chen¹, Megan L. Holtorf¹, William J. Woodward¹, Charles S. Springer¹, Christopher W. Ryan¹, Wei Huang¹

Nine soft-tissue sarcoma patients underwent DCE-MRI scans during the course of a phase I trial of antiangiogenic potentiatiated preoperative chemoradiotherapy. MRI data were acquired before therapy, after two weeks of antiangiogenic therapy only, and after eight more weeks of antiangiogenic therapy plus chemoradiotherapy. The % changes in tumor ROI and histogram median Ktrans values after two weeks provided superior early prediction of therapy pathologic response compared to those in tumor size, ADC, and other DCE-MRI parameters. ROI and median Ktrans changes after two weeks also exhibited a linear relationship with the % necrosis at surgery after ten weeks.